Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective haematopoiesis and cytopenias in peripheral blood. Transformation into acute myeloid leukaemia is a common complication of MDS. Life expectancy varies between nearly normal and early death. MDS were an important issue at last year’s annual meeting of the American Society of Hematology. Like in the years before, the majority of contributions dealt with preclinical aspects. In addition to that, several interesting clinical studies regarding diagnosis and treatment were presented.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bennet JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.
Greenberg P, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.
Font P, Loscertales J, Soto C, et al. Inter-observer discordance with the diagnosis of myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and repurducibility of the threshold of 2 % blasts. Blood. 2013;122:abstract 2768.
Nagata Y, Grossmann V, Okuno Y, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Blood. 2013;122:abstract 521.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher risk myelodysplastic syndromes: a randomised, open-label phase III study. Lancet Oncol. 2009;10:223–32.
Prébet T, Gore DS, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:475–83.
Ades L, Guerci-Bresler A, Makhoul PC, et al. A phase II study of the efficacy and safety of an intensified schedule of azacitidine (AZA) in intermediate-2 and high risk MDS patients. Blood. 2013:abstract 1513.
Garcia-Manero G, Savona M, Gore SD, et al. Hematologic response to oral azacitidine (CC-486) in subjects with WHO-defined RAEB-1 or RAEB-2 myelodysplastic syndromes (MDS). Blood. 2013;122:abstract 1554.
Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–95.
Fenaux P, Giagounidis A, Sellelag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76.
List A, Dewald G, Bennet J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:456–65.
Komrokji RS, Al Ali MH, Pandron E, et al. A phase II clinical trial of lenalidomide and prednisone in low and intermediate-1 risk, non-del(5q) MDS patients. Blood. 2013;122:abstract 1506.
Raza A, Tycko B, Lee S, et al. Oral rigosertib (ON01910.Na) treatment produces an encouraging rate of transfusion independence in lower risk myelodysplastic syndromes (MDS) patients; a genomic methylation profile is associated with responses. Blood. 2013;122:abstract 2745.
Valent P, Krieger O, Stauder R, et al. Iron overload in myelodysplastic syndrmes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest. 2008;38:143–9.
Lyons RM, Marek BJ, Paley CS, et al. 48-month update on survival and AML transformation in a 600-patient registry of lower risk MDS patients. Blood. 2013;122:abstract 2775.
Michallet M, Sobh M, Morisset S, et al. Significant impact of iron chelation after allogeneic hematopoietic stem cell transplantation on disease recurrence: potential of anti-leukemic activity. Blood. 2013;122:abstract 180.
Kantarjian HM, Mufti GJ, Fenaux P, et al. Treatment with romiplostim, a thrombopoietin-receptor agonist, in thrombocytopenic patients with low or intermediate-1 risk myelodysplastic syndrome: updated follow-up results for acute myeloid leukemia and survival from a randomized, double-blind, placebo-controlled study. Blood. 2013;122:abstract 1553.
Prica A, Sholzberg M, Buckstein R. Thrombopoietin (TPO)-receptor agonists in myelodysplastic syndromes (MDS): a systematic review and meta-analysis. Blood. 2013;122:abstract 2806.
Garcia-Manero G, Sekeres MA, List AF, et al. Phase 1 dose-escalation/expansion study of ARRY-614 in patients with IPSS low/int-1 risk myelodysplatic syndromes. Blood. 2013;122:abstract 387.
Garcia-Manero G, Luger SM, Golderg S, et al. A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. Blood. 2013;122:abstract 2752.
Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase II trial of epigenetic modulators vorinostat in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS): initial results of study 6898 of the New York Cancer Consortium. Blood. 2013;122:abstract 386.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Burgstaller, S. Myelodysplastic syndromes (MDS). memo 7, 134–137 (2014). https://doi.org/10.1007/s12254-014-0158-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-014-0158-4